Vibose
Generic Name
Voglibose
Manufacturer
Square Pharmaceuticals Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| vibose 02 mg tablet | ৳ 6.00 | ৳ 60.00 |
Description
Overview of the medicine
Vibose 0.2 mg Tablet contains Voglibose, an alpha-glucosidase inhibitor used to manage postprandial hyperglycemia in patients with type 2 diabetes mellitus. It works by delaying the absorption of carbohydrates from the intestine, thereby reducing the rise in blood glucose levels after meals.
Uses & Indications
Dosage
Adults
Usually 0.2 mg orally, three times daily immediately before each main meal. The dose may be increased to 0.3 mg three times daily if necessary and tolerated.
Elderly
No specific dose adjustment is generally required, but close monitoring is advisable.
Renal_impairment
Use with caution in severe renal impairment. Not recommended in patients with severe renal dysfunction.
How to Take
Take the tablet orally, immediately before the first bite of each main meal. Do not chew the tablet.
Mechanism of Action
Voglibose competitively inhibits alpha-glucosidase enzymes (sucrase, maltase, glucoamylase) in the brush border of the small intestine. This action delays the digestion and absorption of complex carbohydrates and disaccharides, leading to a slower and lower rise in postprandial blood glucose levels.
Pharmacokinetics
Onset
Effect observed within 1-2 hours after administration.
Excretion
Mainly excreted unchanged in the feces. A small amount of absorbed drug and its metabolites are excreted via urine.
Half life
Plasma half-life is very short, typically less than 2 hours for the small amount that is absorbed.
Absorption
Minimally absorbed systemically (less than 0.2%). Primarily acts locally in the gastrointestinal tract.
Metabolism
Minimal systemic metabolism. What little is absorbed is metabolized in the liver.
Side Effects
Contraindications
- •Hypersensitivity to Voglibose or any component of the tablet
- •Diabetic ketoacidosis
- •Severe infection, trauma, or during surgical stress
- •Severe gastrointestinal disorders (e.g., chronic inflammatory bowel disease, colonic ulceration, intestinal obstruction)
- •Large hernia
- •Severe hepatic or renal impairment
Drug Interactions
Metformin
No significant pharmacokinetic interaction, but additive glucose-lowering effects.
Sulfonylureas and Insulin
Increased risk of hypoglycemia; dose adjustment of sulfonylureas/insulin may be necessary.
Corticosteroids, Diuretics, Thyroid hormones
May decrease the hypoglycemic effect of Voglibose.
Storage
Store in a cool, dry place below 30°C. Protect from light and moisture. Keep out of reach of children.
Overdose
Overdose may lead to increased gastrointestinal side effects such as flatulence, abdominal distension, and diarrhea. If Voglibose is taken with other hypoglycemic agents, severe hypoglycemia may occur. Management is symptomatic and supportive.
Pregnancy & Lactation
Not recommended during pregnancy and lactation due to insufficient data. Consult your doctor for alternative management.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
Typically 2-3 years from the date of manufacture, refer to the packaging for exact date.
Availability
Available in pharmacies nationwide
Approval Status
Approved (DGDA, FDA equivalent in other countries)
Patent Status
Off-patent
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine
More Medicines
Explore other medicines you might be interested in
